About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 120638, 3 pages
http://dx.doi.org/10.1155/2013/120638
Clinical Study

Leflunomide as a Corticosteroid-Sparing Agent in Giant Cell Arteritis and Polymyalgia Rheumatica: A Case Series

1Department of Rheumatology, Hospital of Southern Norway Trust Kristiansand, Service Box 416, 4604 Kristiansand, Norway
2Faculty of Medicine, Norwegian University of Science and Technology, Service Box 8905, 7491 Trondheim, Norway

Received 20 May 2013; Revised 10 August 2013; Accepted 11 August 2013

Academic Editor: Joao Eurico Fonseca

Copyright © 2013 Andreas P. Diamantopoulos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Salvarani, F. Cantini, and G. G. Hunder, “Polymyalgia rheumatica and giant-cell arteritis,” The Lancet, vol. 372, no. 9634, pp. 234–245, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Dasgupta, F. A. Borg, N. Hassan et al., “BSR and BHPR guidelines for the management of polymyalgia rheumatica,” Rheumatology, vol. 49, no. 1, pp. 186–190, 2010. View at Scopus
  3. J. Hernández-Rodríguez, M. C. Cid, A. López-Soto, G. Espigol-Frigolé, and X. Bosch, “Treatment of polymyalgia rheumatica: a systematic review,” Archives of Internal Medicine, vol. 169, no. 20, pp. 1839–1850, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. M. De Silva and B. L. Hazleman, “Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study,” Annals of the Rheumatic Diseases, vol. 45, no. 2, pp. 136–138, 1986. View at Scopus
  5. A. D. Mahr, J. A. Jover, R. F. Spiera et al., “Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis,” Arthritis and Rheumatism, vol. 56, no. 8, pp. 2789–2797, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Schmidt and K. J. Warrington, “Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management,” Drugs & Aging, vol. 28, no. 8, pp. 651–666, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. J. S. Smolen, R. Landewé, F. C. Breedveld et al., “EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs,” Annals of the Rheumatic Diseases, vol. 69, no. 6, pp. 964–975, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Gossec, J. S. Smolen, C. Gaujoux-Viala et al., “European league against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies,” Annals of the Rheumatic Diseases, vol. 71, no. 1, pp. 4–12, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. A. W. S. de Souza, M. D. da Silva, L. S. G. MacHado, A. C. D. Oliveira, F. A. G. Pinheiro, and E. I. Sato, “Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study,” Scandinavian Journal of Rheumatology, vol. 41, no. 3, pp. 227–230, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Metzler, N. Miehle, K. Manger et al., “Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis,” Rheumatology, vol. 46, no. 7, pp. 1087–1091, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Adizie, D. Christidis, C. Dharmapaliah, F. Borg, and B. Dasgupta, “Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series,” International Journal of Clinical Practice, vol. 66, no. 9, pp. 906–909, 2012.
  12. B. M. Kirsch, M. Zeyda, K. Stuhlmeier et al., “The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function,” Arthritis Research & Therapy, vol. 7, no. 3, pp. R694–703, 2005. View at Scopus
  13. I. González-Alvaro, A. M. Ortiz, C. Domínguez-Jiménez, A. Aragón-Bodi, B. Díaz Sánchez, and F. Sánchez-Madrid, “Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway,” Annals of the Rheumatic Diseases, vol. 68, no. 10, pp. 1644–1650, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Deng, B. R. Younge, R. A. Olshen, J. J. Goronzy, and C. M. Weyand, “Th17 and th1 T-cell responses in giant cell arteritis,” Circulation, vol. 121, no. 7, pp. 906–915, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. G. G. Hunder, D. A. Bloch, B. A. Michel et al., “The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis,” Arthritis and Rheumatism, vol. 33, no. 8, pp. 1122–1128, 1990. View at Scopus
  16. B. Dasgupta, M. A. Cimmino, H. M. Kremers et al., “2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative,” Arthritis and Rheumatism, vol. 64, no. 4, pp. 943–954, 2012. View at Publisher · View at Google Scholar · View at Scopus